Intermediate Risk Prostate Cancer | List of Frontiers open access articles

Perspective

Published on 14 Nov 2014

Evolution of Hypofractionated Accelerated Radiotherapy for Prostate Cancer – The Sunnybrook Experience

in Radiation Oncology

Hima Bindu Musunuru
Patrick Cheung
Andrew Loblaw

Frontiers in Oncology

doi 10.3389/fonc.2014.00313

10,941 views
17 citations

Original Research

Published on 29 Oct 2020

Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer

in Radiation Oncology

Nima Aghdam
Abigail N. Pepin
Michael Creswell
Kristin Hsieh
Clayton Smith
Nicolette Drescher
Malika Danner
Marilyn Ayoob
Thomas Yung
Siyuan Lei

Frontiers in Oncology

doi 10.3389/fonc.2020.551491

4,546 views
4 citations

Original Research

Published on 14 Jul 2022

Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer

in Radiation Oncology

Pedro C. Lara
Juan I. Rodríguez-Melcón
Amalia Palacios-Eito
Antonio Lozano
Asunción Hervás-Morón
Elena Villafranca
Alfonso Gómez-Iturriaga
Gemma Sancho
Xavier Maldonado

Frontiers in Oncology

doi 10.3389/fonc.2022.891886

6,014 views
5 citations

Case Report

Published on 07 Jan 2021

Utilization of Iodinated SpaceOAR Vue™ During Robotic Prostate Stereotactic Body Radiation Therapy (SBRT) to Identify the Rectal–Prostate Interface and Spare the Rectum: A Case Report

in Radiation Oncology

Dylan Conroy
Kelly Becht
Matthew Forsthoefel
Abigail N. Pepin
Siyuan Lei
Abdul Rashid
Brian Timothy Collins
Jonathan W. Lischalk
Simeng Suy
Nima Aghdam

Frontiers in Oncology

doi 10.3389/fonc.2020.607698

7,377 views
13 citations

Original Research

Published on 16 Jan 2025

Long-term outcomes of LDR-brachytherapy for localized prostate cancer

in Radiation Oncology

Lauri Mäkelä
Anssi Pétas
Arto Mikkola
Harri Visapää

Frontiers in Oncology

doi 10.3389/fonc.2024.1326355

3,499 views
2 citations

Original Research

Published on 24 Jul 2017

Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?

in Radiation Oncology

Shaan Kataria
Harsha Koneru
Shan Guleria
Malika Danner
Marilyn Ayoob
Thomas Yung
Siyuan Lei
Brian T. Collins
Simeng Suy
John H. Lynch

Frontiers in Oncology

doi 10.3389/fonc.2017.00157

13,855 views
18 citations

Original Research

Published on 09 Dec 2021

Influence of Biopsy Gleason Score on the Risk of Lymph Node Invasion in Patients With Intermediate-Risk Prostate Cancer Undergoing Radical Prostatectomy

in Genitourinary Surgery and Interventions

Mike Wenzel
Felix Preisser
Benedikt Hoeh
Maria N. Welte
Clara Humke
Clarissa Wittler
Christoph Würnschimmel
Andreas Becker
Pierre I. Karakiewicz
Felix K. H. Chun

Frontiers in Surgery

doi 10.3389/fsurg.2021.759070

2,581 views
4 citations

Articles

Evolution of Hypofractionated Accelerated Radiotherapy for Prostate Cancer – The Sunnybrook Experience

Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer

Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer

Utilization of Iodinated SpaceOAR Vue™ During Robotic Prostate Stereotactic Body Radiation Therapy (SBRT) to Identify the Rectal–Prostate Interface and Spare the Rectum: A Case Report

Long-term outcomes of LDR-brachytherapy for localized prostate cancer

Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?

Influence of Biopsy Gleason Score on the Risk of Lymph Node Invasion in Patients With Intermediate-Risk Prostate Cancer Undergoing Radical Prostatectomy